Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

American Journal of Public Health logoLink to American Journal of Public Health
. 2001 May;91(5):791–793. doi: 10.2105/ajph.91.5.791

Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence.

S R Friedman 1, T Perlis 1, D C Des Jarlais 1
PMCID: PMC1446682  PMID: 11344889

Abstract

OBJECTIVES: This study sought to assess relations of laws prohibiting over-the-counter syringe sales (anti-OTC laws) to population prevalence of injection drug users and HIV prevalence or incidence among 96 US metropolitan areas. METHODS: A cross-sectional analysis was used. RESULTS: Metropolitan areas with anti-OTC laws had a higher mean HIV prevalence (13.8% vs 6.7%) than other metropolitan areas (pseudo-P < .001). In 83 metropolitan areas with HIV prevalence of less than 20%, anti-OTC laws were associated with HIV incidence rates of 1% or greater (pseudo-P < .001). Population proportions of injection drug users did not vary by presence of anti-OTC laws. CONCLUSIONS: Anti-OTC laws are not associated with lower population proportions of injection drug users. Laws restricting syringe access are associated with HIV transmission and should be repealed.

Full Text

The Full Text of this article is available as a PDF (67.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battjes R. J., Pickens R. W., Amsel Z. Introduction of HIV infection among intravenous drug abusers in low prevalence areas. J Acquir Immune Defic Syndr. 1989;2(6):533–539. [PubMed] [Google Scholar]
  2. Case P., Beckett G. A., Jones T. S. Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 (Suppl 1):S94–101. doi: 10.1097/00042560-199802001-00017. [DOI] [PubMed] [Google Scholar]
  3. Caussy D., Weiss S. H., Blattner W. A., French J., Cantor K. P., Ginzburg H., Altman R., Goedert J. J. Exposure factors for HIV-1 infection among heterosexual drug abusers in New Jersey treatment programs. AIDS Res Hum Retroviruses. 1990 Dec;6(12):1459–1467. doi: 10.1089/aid.1990.6.1459. [DOI] [PubMed] [Google Scholar]
  4. Compton W. M., 3rd, Cottler L. B., Decker S. H., Mager D., Stringfellow R. Legal needle buying in St. Louis. Am J Public Health. 1992 Apr;82(4):595–596. doi: 10.2105/ajph.82.4.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. D'Aquila R. T., Peterson L. R., Williams A. B., Williams A. E. Race/ethnicity as a risk factor for HIV-1 infection among Connecticut intravenous drug users. J Acquir Immune Defic Syndr. 1989;2(5):503–513. [PubMed] [Google Scholar]
  6. Des Jarlais D. C., Friedman S. R., Novick D. M., Sotheran J. L., Thomas P., Yancovitz S. R., Mildvan D., Weber J., Kreek M. J., Maslansky R. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989 Feb 17;261(7):1008–1012. doi: 10.1001/jama.261.7.1008. [DOI] [PubMed] [Google Scholar]
  7. Friedland G. H., Harris C., Butkus-Small C., Shine D., Moll B., Darrow W., Klein R. S. Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. Arch Intern Med. 1985 Aug;145(8):1413–1417. [PubMed] [Google Scholar]
  8. Friedman S. R., Jose B., Deren S., Des Jarlais D. C., Neaigus A. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium. Am J Epidemiol. 1995 Oct 15;142(8):864–874. doi: 10.1093/oxfordjournals.aje.a117726. [DOI] [PubMed] [Google Scholar]
  9. Groseclose S. L., Weinstein B., Jones T. S., Valleroy L. A., Fehrs L. J., Kassler W. J. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers--Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):82–89. [PubMed] [Google Scholar]
  10. Grund J. P., Heckathorn D. D., Broadhead R. S., Anthony D. L. In eastern Connecticut, IDUs purchase syringes from pharmacies but don't carry syringes. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):104–105. doi: 10.1097/00042560-199509000-00016. [DOI] [PubMed] [Google Scholar]
  11. Hahn R. A., Onorato I. M., Jones T. S., Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA. 1989 May 12;261(18):2677–2684. [PubMed] [Google Scholar]
  12. Holmberg S. D. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996 May;86(5):642–654. doi: 10.2105/ajph.86.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kaplan G. A., Pamuk E. R., Lynch J. W., Cohen R. D., Balfour J. L. Inequality in income and mortality in the United States: analysis of mortality and potential pathways. BMJ. 1996 Apr 20;312(7037):999–1003. doi: 10.1136/bmj.312.7037.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lynch J. W., Kaplan G. A., Pamuk E. R., Cohen R. D., Heck K. E., Balfour J. L., Yen I. H. Income inequality and mortality in metropolitan areas of the United States. Am J Public Health. 1998 Jul;88(7):1074–1080. doi: 10.2105/ajph.88.7.1074. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES